Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst

Biogen Inc. (BIIB) announced an update on their ongoing clinical study.

Biogen Inc. (BIIB) is running a Phase 2 study called “A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis.” The goal is to test safety and brain effects of BIIB091 alone and with diroximel fumarate in adults with relapsing multiple sclerosis, a key growth area for the company.

The study tests an oral drug called BIIB091, designed to reduce disease activity in relapsing multiple sclerosis. It is used alone and in combination with Biogen’s existing therapy diroximel fumarate (DRF) to see if adding BIIB091 can improve control of brain inflammation and relapses.

This is an interventional, randomized study where people are assigned by chance to different treatments. It uses a blinded design so neither patients nor study staff know who is receiving BIIB091, DRF, combinations, or placebo, and the main goal is to assess treatment for active disease, not prevention or diagnosis.

The trial has two parts. In Part 1, participants receive either high-dose BIIB091, low-dose BIIB091, or standard-dose DRF, helping select the best BIIB091 dose for Part 2.

In Part 2, new participants receive either DRF alone or DRF plus BIIB091 at different dose levels. This stepwise plan lets Biogen refine dosing while measuring safety and brain scans across both parts of the study.

The study began enrolling after first submission on 23 March 2023, marking the formal launch for this asset in relapsing multiple sclerosis. As a Phase 2 treatment trial, the focus is on proof of concept and dosing rather than broad approval.

The status is now listed as completed, which means patient visits and dosing are done. The primary completion occurred before the most recent update, allowing Biogen to lock data and move toward analysis and disclosure.

The latest update to the record was submitted on 18 February 2026, signaling that Biogen has refreshed protocol or status details. No results are posted yet, so investors still lack visibility on efficacy and full safety, although completion reduces development risk.

This update is modestly positive for BIIB, as a completed Phase 2 study in relapsing multiple sclerosis supports the company’s pipeline beyond existing products like Tecfidera and Vumerity. If results are favorable, BIIB091 could strengthen Biogen’s competitive stance versus Novartis, Roche, and others in the large market for oral MS drugs.

Near term, the key catalyst will be top-line data, which could drive meaningful share moves depending on strength versus DRF alone and safety signals. Until data readout, sentiment is likely to be cautiously optimistic, with the completed status lowering execution risk but not yet changing fundamental valuation.

The study record has been recently updated and is now marked completed, and further details are available on the ClinicalTrials portal.

To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.